



National Coverage Determination (NCD) Update

Benefit: Transcatheter Aortic Valve Replacement (TAVR)

Effective Date: June 21, 2019

The Centers for Medicare and Medicaid Services (CMS) reported on June 21, 2019 that they will cover transcatheter aortic valve replacements (TAVRs) for the treatment of symptomatic aortic valve stenosis when performed in accordance with the indication approved by the Food and Drug Administration (FDA), and for uses not expressly listed as an approved indication by the FDA, when performed as part of an approved clinical study.

For the CMS decision memo, go to <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=293>

MCS Classicare is a product subscribed by MCS Advantage, Inc. MCS Advantage, Inc. complies with federal civil rights laws applicable and does not discriminate on grounds of race, color, national origin, age, disability or sex. MCS Advantage, Inc. cumple con las leyes federales de derechos civiles aplicables y no discrimina por motivos de raza, color, nacionalidad, edad, discapacidad o sexo. MCS Advantage, Inc. 遵守適用的聯邦民權法律規定，不因種族、膚色、民族血統、年齡、殘障或性別而歧視任何人。ATTENTION: If you speak English, language assistance services, free of charge, are available to you. Call 1.866.627.8183 (TTY: 1.866.627.8182). ATENCIÓN: Si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1.866.627.8183 (TTY: 1.866.627.8182). 注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1.866.627.8183